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Abstract
Human scalp skin and hair follicles (HFs) are extra-pituitary sources of prolactin (PRL). However, the intracutaneous
regulation of PRL remains poorly understood. Therefore we investigated whether well-recognized regulators of pituitary PRL
expression, which also impact on human skin physiology and pathology, regulate expression of PRL and its receptor (PRLR)
in situ. This was studied in serum-free organ cultures of microdissected human scalp HFs and skin, i.e. excluding pituitary,
neural and vascular inputs. Prolactin expression was confirmed at the gene and protein level in human truncal skin, where
its expression significantly increased (p = 0.049) during organ culture. There was, however, no evidence of PRL secretion into
the culture medium as measured by ELISA. PRL immunoreactivity (IR) in female human epidermis was decreased by
substance P (p = 0.009), while neither the classical pituitary PRL inhibitor, dopamine, nor corticotropin-releasing hormone
significantly modulated PRL IR in HFs or skin respectively. Interferon (IFN) c increased PRL IR in the epithelium of human HFs
(p = 0.044) while tumour necrosis factor (TNF) a decreased both PRL and PRLR IR. This study identifies substance P, TNFa and
IFNc as novel modulators of PRL and PRLR expression in human skin, and suggests that intracutaneous PRL expression is not
under dopaminergic control. Given the importance of PRL in human hair growth regulation and its possible role in the
pathogenesis of several common skin diseases, targeting intracutaneous PRL production via these newly identified
regulatory pathways may point towards novel therapeutic options for inflammatory dermatoses.
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Background
Whilst prolactin (PRL) is appreciated for its role in the
modulation of hair growth, both in human and other mammalian
species [1,2], less attention has been afforded to the role(s) of PRL
in cutaneous biology and pathology in general. However, several
recent publications have reawakened interest in the ‘‘PRL-skin’’
connection, particularly in the context of a possible role for PRL in
psoriasis [3,4,5,6] and systemic lupus erythematosus [7].
However, in human skin, the published literature has only
confirmed scalp skin and scalp hair follicles (HFs) as cutaneous
sources of extra-pituitary PRL production [1], although PRL
expression has also been reported in human dermal fibroblasts in
vitro [8]. Also, El-Khateeb et al. [5] recently reported increased
levels of PRL in blister fluid from lesional psoriatic skin in psoriasis
patients when compared to uninvolved skin and skin from healthy
subjects. Moreover, these levels exceeded serum PRL levels;
evidence that PRL is produced intracutaneously. In contrast,
Slominski et al failed to identify PRL gene expression in both
normal and pathological skin [9], and Bjo¨rntorp et al could not
identify PRL gene expression in involved skin in psoriasis using
reverse transcriptase polymerase chain reaction [10]. Given the
pro-inflammatory cutaneous cytokine milieu which is present in
psoriasis, we speculated that cytokines, for example tumour
necrosis factor alpha (TNFa) and interferon gamma (IFNc), may
up-regulate intracutaneous PRL production.
Furthermore, although the regulation of pituitary PRL synthesis
and release has been extensively studied [11], albeit almost
exclusively in rodent models [12], much less is known about the
regulation of extra-pituitary PRL production [13] (Table S1),
namely in human skin. Given that the ‘‘regulation of’’ human
‘‘extra-pituitary PRL release can only be studied in human cells
and tissues’’ [12], human skin and HFs provide an invaluable
resource for studying the regulation of extra-pituitary PRL gene
and protein expression. Conventionally, the regulation of extra-
pituitary PRL synthesis and secretion was considered to differ from
that in the pituitary, based on the assumption of dual promoter
usage in extra-pituitary versus pituitary tissues, the latter involving
the pituitary specific transcription factor Pit-1 [14,15]. However,
recent studies exploring the autocrine/paracrine actions of PRL
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[16] have recapitulated the pro-apoptotic effects of PRL observed
in the HF [1], inviting the hypothesis that the HF itself can be
utilized to study the regulation and autocrine/paracrine action of
PRL in humans [17].
Given (i) the lack of any universal PRL stimulatory/inhibitory
factor [18], (ii) that little is known about the regulation of PRL
receptor (PRLR) expression in extra-pituitary sites [19], and (iii)
that conclusions drawn from studies determining the regulation of
PRL and PRLR expression in other sites cannot be reliably
extrapolated to the skin, studies with human skin and HFs are best
placed to determine the regulation of intracutaneous PRL and
PRLR. Furthermore, the skin and HF organ culture model has
already provided novel insights into the in vitro regulation of PRL
and PRLR in human skin and offers unparalleled accessibility and
clinical utility [20,21]. Given the major endocrine functions of skin
[22,23,24,25,26], a source and target of PRL [1], and that PRL is
a potential player in skin and hair diseases [3,4,5,6,7,27,28,29] a
comprehensive analysis of the intracutaneous regulation of PRL
and PRLR is required.
Therefore we determined whether healthy corporal human skin
expresses PRL and PRLR expression at the gene and protein level,
and establish whether there are any time-dependent changes in
cutaneous PRL and PRLR expression in organ culture in vitro.
Moreover, we asked whether selected regulators of pituitary PRL
synthesis and/or secretion and pro-inflammatory cytokines alter
epidermal and follicular PRL expression. Finally, we examined
whether there are any differences between the regulation of PRLR
expression in the skin and the HF.
Materials and Methods
Human skin was obtained as by-products of cosmetic surgery,
after written informed consent was provided. Full ethical approval
was obtained from the University of Lu¨beck ethics committee,
according to the Helsinki Declaration. For the determination of
PRL and PRLR immunoreactivity (IR), immunohistochemistry
was performed as described previously [20]. In summary, after
drying at room temperature and fixing in acetone, sections were
treated with 3% hydrogen peroxide to block any endogenous
peroxidase. After washing in tris-buffered sulphate (TBS), sections
were treated with an avidin and biotin blocking kit (Vector,
Burlingame, CA) and then pre-incubated with 10% normal rabbit
serum. Prolactin antibody (Prolactin (C-17) goat polyclonal
antibody, raised against a peptide mapping near the C-terminus
of prolactin of human origin, sc-7805, Santa Cruz, CA)[1] was
then applied overnight at 4uC, 1:50 dilution in TBS with 2%
normal rabbit serum. Negative control was by the omission of the
primary antibody and overnight incubation with 2% normal
rabbit serum in TBS. After further washes with TBS, rabbit anti-
goat biotinylated antibody, 1:200 dilution in TBS with 2% normal
rabbit serum, was applied for 45 minutes at room temperature.
After further washes, the avidin-biotin peroxidase kit was used for
30 minutes at room temperature (Vector, Burlingame, CA). 3-
amino-9-ethyl-carbazole (AEC) (Vector, Burlingame, CA) was
then used as the chromogen. Sections were then counterstained
with Haematoxylin and mounted with Faramount (Dako,
Glostrup, DK).
For PRLR immunohistochemistry, PRLR antibody (mouse
monoclonal PRLR antibody, reacts with the extracellular portion
of the receptor, isotype IgG1, SM5033P, Acris antibodies,
DE)[30,31] was applied (1:50) in antibody diluent (DCS Innova-
tive Diagnostik-Systeme, Hamburg, DE) overnight at 4uC and the
labelled streptavidin biotin (LSAB) (DCS Innovative Diagnostik-
Systeme, Hamburg, DE) method was used. The application of
antibody diluent alone served as the negative control. AEC
(Vector, Burlingame, CA) was again applied as the chromogen,
prior to counterstaining with haematoxylin and mounting with
Faramount (Dako, Glostrup, DK).
Immunoreactivity for PRL and PRLR in the HF and sebaceous
gland served as internal positive controls, based on previously
published expression patterns [1,20]. Four millimetre punch
biopsies were obtained from redundant corporal skin. (for PRL
immunohistochemistry, R:n = 3 Age: 28–57 years, for PRLR
immunohistochemistry, R:n = 3 Age:28–63). The redundant skin
from the 28 year old female was used in both PRL and PRLR
analyses.
Investigating the temporal regulation of PRL
In order to investigate the effect of organ culture itself on PRL
and PRLR IR, 4 mm punch biopsies were obtained from
redundant corporal skin, by-products of cosmetic surgery, (female,
n = 3, age 42–63 years) and placed in serum free culture medium
as described previously [20,32]. Culture medium consisted of
William’s E (Biochrome, Berlin DE), supplemented with 2 mmol/l
L-glutamine (Invitrogen, Paisley, UK), 10 ng/ml hydrocortisone
(Sigma-Aldrich), 10 mg/ml insulin (Sigma Aldrich) and antibiotic
mixture (100 IU/ml penicillin and 10 mg/ml streptomycin) [32].
The medium was changed every 48 hours. After 7 days in culture,
skin was either embedded in cryomatrix (Thermo Shandon,
Cheshire, UK), snap frozen in liquid nitrogen, sectioned (7 mm)
and stained for PRL/PRLR as above or directly frozen for
quantitative ‘‘real-time’’ PCR (qRT-PCR) studies.
Investigating the intracutaneous regulation of PRL
Microdissected female anagen VI HFs were isolated from
redundant scalp skin as described [1]. Microdissected HFs and/or
full thickness skin [32] were cultured in supplemented serum-free
culture medium for either 24 hours or 7 days. For skin 24 hour
skin organ culture, the following substances were tested. Substance
P (Sub P, 100 nM, 2R subjects aged 45–46 years)[33], corticotro-
pin releasing hormone (CRH, 1 mM, 3R subjects aged 45–57
years)[34], triiodothyronine (T3, 100 pM)[35] or thyroxine (T4,
100 nM) 3–5R aged 45–71 years) [35,36].
To enable a comparison between the effects of PRL on PRLR
protein expression in the skin and HF, 7 day organ culture with
PRL (400 ng/ml) was used. For skin organ culture, skin from 3R
subjects (aged 42–63 years), was compared with HFs from 4R
subjects (aged 49–68 years). For the remaining HF studies, the
following substances were used, dopamine (DA 10–1000 nM, 3R
aged 47–68 years)[37], TNFa (0.5–50 ng/ml, 3R subjects aged
49–68 years)[38] and IFNc (75 IU/ml, 3R subjects aged 44–68
years, added only at day 1 and 5) [39]. The concentration of IFNc
(75 IU/ml) was selected given that we have previously shown that
75 IU/ml IFNc does not induce catagen, while higher doses
would have greatly reduced the percentage of anagen HFs.
[39,40]. All HF experiments started with 12–18 HFs. At the end of
each culture, only anagen VI HFs were used for analysis to avoid
any confounding effects of hair cycle phase on PRL and PRLR
expression [1]. The regulation of PRL on its own expression could
not be determined since the skin and HF have endogenous PRL
production [1,20,21], preventing differentiation of endogenous
from exogenous PRL by immunohistochemistry. Cultured skin
and HFs were then cryosectioned (HFs:6 mm, skin:7 mm) and
stained for PRL and/or PRLR IR as described above.
For qRT-PCR analyses, skin and/or HFs were treated for either
24–48 hours or 7 days (see figure legends for details).
The Regulation of Prolactin in Human Skin
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Phosphorylated STAT5 studies
In order to determine whether PRLR-mediated signaling
involved the canonical JAK2/STAT5 pathway, phosphorylated
STAT5 levels were examined using immunohistochemistry,
employing phospo-STAT5 (Tyr694) rabbit monoclonal antibody
to detect STAT5a and b proteins when phosphorylated at Tyr 694
(Cell Signaling, C11C5; 1:100 dilution). After fixation in acetone
and blocking of endogenous peroxidase, blocking solution (1%
horse serum in 3% BSA-TBS-Tween) was applied for 60 minutes,
followed by overnight incubation with the primary antibody at
4uC. Horse anti-rabbit biotinylated secondary antibody (Vector
lab BA-1100; 1:200 dilution in TBS-T +2% horse serum) was then
applied for 30 minutes at room temperature, followed by the
Vectastain Elite ABCH (Vector lab, PK-6100) detection technique
as described above, with 3,3’ diaminobenzidine (DAB) used as the
chromogen.
Quantitative ‘‘real-time’’ PCR studies
Specific mRNA transcripts of were analyzed by qRT-PCR as
described (40), using TaqMan primers and probes (PRL, Assay ID:
Hs 00168730_m1; PRLR, Assay ID: Hs00168739_m1). As
internal housekeeping gene controls for the qRT-PCR experi-
ments, transcripts of glyceraldehyde 3-phosphate dehydrogenase
(GAPDH, Assay ID: Hs 99999905_m1), b-actin (ACTB, Assay ID:
Hs 99999903_m1), and cyclophilin A (PPIA, Assay ID:
Hs99999904_m1) were determined. The amount of the afore-
mentioned transcripts was normalised to those of the most stable
control gene using the DDCT method. All experiments were
performed in triplicate. The expression of the target genes was
normalized to that of the relevant control group and independent
data from 2–3 different donors were pooled, and expressed as fold
changes. Statistical analysis was performed by paired or unpaired
two-sample Student’s t-test.
ELISA studies
To determine whether there was any evidence of PRL secretion
into the culture medium, ELISA was performed on conditioned
culture media from two subjects from day one and day five. This
media was from skin (R 31 years) and HF organ culture (R 52 years)
respectively. ELISA was performed as described previously [41].
In brief, 100 ml of conditioned media was added to each well. After
1 hour of shaking at room temperature, subsequently washing with
buffer, 100 ml of rabbit-anti human PRL primary detected
antibody was added (Dako A0569 1:2500). After 1 hour of
shaking at room temperature, then washing, HRP-conjugated
detection antibody (Cell signaling 7074, rabbit IgG, 1:5000) was
added for 1 hour at room temperature. After washing, TMB was
added to each well for 15–20 minutes (in the dark), followed by
stop solution (50 ml). The plate was then read at 450 nm within
20 minutes of the addition of the stop buffer. The lower limit of
detection of PRL was 0.445 ng/ml.
Outer root sheath keratinocyte cultures
Given that PRL and PRLR are prominently expressed in the
outer root sheath (ORS) compartment of human HFs, human
ORS keratinocyte cell culture was performed to verify whether
PRL and PRLR transcripts are also expressed in isolated HF
keratinocytes. Moreover, we checked the expression of PRL and
PRLR after treatment with TNFa (5 ng/ml for 6 hours) and
tested whether this treatment influenced expression of STAT5, a
key molecule in PRLR mediated signaling. ORS keratinocytes
were obtained from human HFs (2R subjects aged 25–26 years)
after digestion with trypsin [42] and cultured in serum-free media
[21].
Statistical Analysis
Standardised reference areas in the ORS were measured for
PRL and PRLR IR using National Institute of Health Image J
software (Bethesda, Maryland, USA, See - Supplement 1)
[20,34,43]. 2–6 measurements were taken for each anagen HF
and the mean IR calculated. For epidermal immunohistomorpo-
metric analyses, IR of the entire epidermis, excluding the stratum
corneum, was measured in 3 high power fields (x200 magnifica-
tion). For statistical analyses, data were checked for normal
distribution by D’Agostino and Pearson normality test. Depending
on the data distribution and the number of groups investigated,
Student’s t-test/one way ANOVA (with Bonferroni’s post hoc test)
or Mann-Whitney U-test/Kruskal-Wallis test (with Dunn’s mul-
tiple comparison post hoc test) were used where appropriate.
Statistical analysis was performed using GraphPad Prism,
Version 5 (San Diego California, USA). p,0.05 was considered
as statistically significant and results were expressed as the mean
+/2 standard error of the mean (SEM). To combine the results
from the independent quantitative (immuno-) histomorphometry
experiments, the results from the treatment groups were normal-
ized to the control group (set at 100) and the results were pooled.
Significance was determined as *p,0.05, **p,0.01, ***p,0.001.
Results
PRL immunoreactivity is present in corporal skin and PRL
gene transcription can increase during human skin organ
culture
To determine whether PRL protein was expressed in corporal
skin, PRL immunohistochemistry was performed. Prolactin
specific staining was present in each subject, in a cytoplasmic
distribution in the basal epidermal layer (Fig 1A–C). This was
consistent with the previously described PRL distribution pattern
in scalp skin, whose specificity had been established by RT-PCR
analyses and by studying pituitary sections [20]. By qRT-PCR,
PRL transcripts were below the detection limit at day 0 in both
subjects, but became detectable by day 7 (Fig 1F and G). In line
with this, epidermal PRL protein IR significantly increased during
human skin culture as measured by quantitative immunohisto-
morphometry (Fig 1H–K). Interestingly, in a third, likely
postmenopausal subject, PRL gene expression was detectable at
day 0, but significantly decreased in organ culture (data not
shown).
PRLR immunoreactivity and gene expression is present in
corporal skin and decreases during organ culture
Next, we determined the expression of PRLR in human
corporal by immunohistochemistry. PRLR protein expression was
most notable in the basal epidermal layer, again in a cytoplasmic
distribution (Fig 2A–C) in each skin site. In contrast to PRL gene
expression, PRLR gene expression was detectable in all subjects at
day 0, and transcript levels were significantly reduced by day 7 (Fig
2E). This was paralleled by a reduction in PRLR IR between day
0 and 7 (Fig 2F–I). This reciprocal relationship between PRL and
PRLR gene expression recapitulates previous observation in
murine skin [2].
The Regulation of Prolactin in Human Skin
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Substance P decreases PRL expression in human
epidermis
Given that substance P is a recognized potential regulator of
pituitary PRL secretion [11] and plays an important role in
neurogenic skin inflammation [33], the effect of Substance P on
epidermal PRL was determined by quantitative immunohisto-
morphometry. Substance P treatment decreased PRL IR (black
arrows) compared to control skin (Fig 3 A–C).
Neither CRH nor thyroid hormones regulate PRL
expression in human epidermis
As a central hormone in the systemic stress response, which may
also regulate pituitary PRL secretion [44,45], we next investigated
the effect of CRH on epidermal PRL expression. CRH had no
effect on PRL expression (p = 0.24) (Fig S1A–E). An example of
the epidermal area of evaluation is shown in Fig S1A. Similarly,
thyroid hormones (T3 and T4) did not alter epidermal PRL or
PRLR IR. Furthermore, epidermal PRLR gene expression was
not influenced by T3 or T4 over the same time period, when
compared to the control skin (Fig S2 A–J).
IFNc increases PRL expression in the HF outer root
sheath whilst TNFa decreases follicular PRL expression
Since pituitary PRL secretion may be regulated by IFNc and
TNFa, albeit in rodent studies [46,47,48,49], and since these
cytokines [50,51] and PRL [3,5,28,52,53] have been implicated in
the pathogenesis of psoriasis, we also examined whether these
prototypic pro-inflammatory cytokines influence PRL and PRLR
expression in the HF. This examination showed that PRL IR in
ORS keratinocytes in situ was significantly increased by IFNc
treatment (Fig 4A–D, black arrows). Since 50 ng/ml of TNFa
resulted in increased catagen induction (HF regression) (data not
shown) [38], resulting in too few anagen HFs for further analysis,
only lower TNFa concentrations could be followed up at the
protein expression level. This revealed that PRL expression was
unaffected by TNFa 0.5 ng/ml, but significantly decreased by
5 ng/ml. (Fig 4E–H).
Dopamine has no effect on PRL or PRLR IR in the outer
root sheath of human HFs at the gene or protein level
Consistent with the conventional wisdom that extra-pituitary
PRL production is not under dopaminergic control [18,54],
dopamine treatment of HFs did not alter PRL IR (Fig S3A–E).
Indeed, PRLR expression at the gene and protein level (10–
Figure 1. Prolactin immunoreactivity is present in corporal skin and its gene transcription can increase during culture. Prolactin (PRL)
immunoreactivity (IR) is demonstrated in (A) axillary skin from a 49 year old R, (B) axillary skin from a 28 year old R and (C) thigh skin from a 57 year old
R. The black arrows show that the IR was most prominent in the basal layer of the epidermis, in a cytoplasmic distribution, in non-scalp skin. (D)
Omission of the primary antibody served as the negative control and (E) the hair follicle outer root sheath keratinocytes and sebaceous gland served
as internal positive controls. (F) PRL gene expression was below the level of detectability at day 0, but became detectable by day 7 during serum free
organ culture in breast skin (from a 42 year old R) and (G) abdominal skin (from 63 year old R). At the protein expression level, PRL IR also increased
between (H) day 0 and (I) day 7. (J) High magnification of PRL IR. Quantitative measurement of PRL IR, using Image J software is shown in (K). Results
pooled from 3 females aged 42–63 years. Increased protein expression correlated with increased gene expression in two subjects over the same time
period. However, in one subject PRL gene expression was readily detectable at day 0, but decreased significantly during organ culture (data not
shown). qRT-PCR results could not be normalized, combined and expressed as fold change from day 0, as no PRL gene expression was detected at
day 0 in 2/3 subjects. All scale bars represent 50 mm.
doi:10.1371/journal.pone.0060819.g001
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Figure 2. Prolactin receptor immunoreactivity and gene expression is present in corporal skin and decreases during culture. PRL
receptor (PRLR) IR is present in the epidermis of corporal from three female subjects aged 28–63 years (A–C). This IR was present in the basal layer of
the epidermis (black arrows) in a cytoplasmic distribution. (D) Omission of the primary antibody served as the negative control. (E) PRLR gene
expression was detectable in corporal skin from three female subjects (results pooled and expressed as fold change), aged 42–63 years, at day 0 and
decreased significantly during serum-free organ culture. PRLR protein expression also significantly decreased during organ culture (F–H). High
magnification of PRLR IR shown in (I). Protein expression results were pooled from 3 females aged 42–63 years as in Fig 1(J). Representative
photomicrographs of PRLR IR during organ culture are both taken from abdominal skin from 63 year old R. All scale bars represent 50 mm.
doi:10.1371/journal.pone.0060819.g002
Figure 3. Substance P decreases PRL immunoreactivity in human epidermis. Epidermal PRL IR (black arrows) was examined in full-thickness
human skin organ culture. (A) PRL IR in the control group was significantly greater than that in (B) Substance P treated skin. PRL IR was measured
using Image J software, showing that (C) epidermal PRL IR was significantly decreased by 100 nM Substance P treatment (p = 0.009). Results were
pooled from R subjects aged 45 and 46 years. Scale bars represent 50 mm.
doi:10.1371/journal.pone.0060819.g003
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1,000 nM), was unaffected by the range of dopamine concentra-
tions tested (Fig S4A–H). A range of dopamine concentrations was
tested given that dopamine’s effect on PRL secretion is not linear,
and low concentrations have even been found to stimulate PRL
release in the lactotrophes in vitro [55].
IFNc does not alter PRLR gene or protein expression in
human HF epithelium
In contrast to its effect on PRL expression, PRLR IR in the
outer root sheath of HFs was unchanged by treatment with IFNc
(Fig S5A–D). Also, IFNc exerted no consistent regulatory effect on
PRLR gene expression in the HF (Fig S5E).
TNFa significantly decreases PRLR IR in the HF epithelium
Interestingly, TNFa (0.5–50 ng/ml) significantly decreased
PRLR IR in the ORS of human HFs (Fig 5A–E) after 7 days.
There was no significant effect of 50 ng/ml TNFa treatment on
PRLR gene expression after 48 hours (Fig 5F). For qRT-PCR
studies all HFs were used as they could not be histologically staged,
whilst for PRLR IR immunohistochemistry only anagen HFs
could be analysed.
TNFa treatment decreases PRL gene expression in
cultured ORS keratinocytes
Given that PRL and PRLR IR was prominent in the ORS, we
checked PRL and PRLR gene expression in cultured ORS
keratinocytes, which expressed PRL and PRLR at the gene level.
As in organ-cultured intact human HFs, TNFa 5 ng/ml
significantly decreased PRL gene expression in isolated, cultured
ORS keratinocytes (Fig 6A). In contrast, TNFa 5 ng/ml increased
both PRLR and STAT5a gene expression (whereas levels of
STAT5b were not affected) (Fig 6B–D). This shows that the effects
of TNFa on PRL gene expression may be independent of the HF
mesenchyme.
PRL increases STAT5 phosphorylation in serum-free
organ culture
In order to determine whether the PRLRs detected in human
skin are functional, we also examined whether PRL treatment
activated epidermal STAT5 phosphorylation. STAT5 is the main
mediator of PRLR signalling [56] and is expressed in human
epidermis [57]. Indeed, at the end of the culture period, STAT5
phosphorylation was clearly increased in PRL treated skin from
Figure 4. IFNc increases PRL immunoreactivity in the hair follicle, whilst TNFa decreases follicular PRL immunoreactivity. (A) PRL IR in
control hair follicle outer root sheath keratinocytes (black arrows), (B) after INFc treatment and (C) negative control. (D) PRLR IR is significantly
increased by INFc treatment (p = 0.044). Results were pooled from 3 R subjects (Aged 44–68), 14–16 HFs per group in total. In contrast, TNFa 5 ng/ml
significantly decreased PRL IR (E). PRL IR is shown in (F) control hair follicles and those treated with (G) TNFa 0.5 ng/ml and (H) TNFa 5 ng/ml. Results
were pooled from 3 R subjects (Aged 49–68) 18–23 HFs per group in total. Scale bars represent 50 mm.
doi:10.1371/journal.pone.0060819.g004
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Figure 5. TNFa significantly decreases PRLR immunoreactivity in the outer root sheath of hair follicles. (A) PRLR IR in the outer root
sheath of control hair follicles (black arrows) was reduced in comparison PRLR IR after treatment with TNFa at concentrations of (B) 0.5 ng/ml and (C)
5 ng/ml. (D) Negative control. (E) Quantitative analysis confirms decreased PRLR IR after TNFa treatment (13–17 HFs per group in total). Results were
pooled from same subjects described in Fig 4. (F) Pooled results of PRLR steady state gene expression in two subjects (R aged 53 and 66 years)
showed no significant effect of 50 ng TNFa treatment after 48 hours. Scale bars represent 50 mm.
doi:10.1371/journal.pone.0060819.g005
Figure 6. PRL and PRLR are detectable in cultured outer root sheath keratinocytes. (A) PRL and PRLR were detectable in ORS keratinocytes
in culture, consistent with the in-situ protein data. TNFa treatment (5 ng/ml) decreased PRL but (B) increased PRLR gene expression. There was also
evidence that TNFa modulated STAT5a expression, a key downstream signal of PRLR, but not STAT5b (C–D).
doi:10.1371/journal.pone.0060819.g006
The Regulation of Prolactin in Human Skin
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three different individuals (Fig. 7A–C), thus indicating function-
ality of PRLR-mediated signalling in human epidermis.
The regulation of intracutaneous PRLR expression does
not appear to be compartment-specific
Finally, we assessed whether PRL impacts on the intracutaneous
expression of its own receptor and whether there are any
differences in the regulation of PRLR by its ligand between
defined skin compartments. As expected, prominent PRLR IR was
seen in the ORS and did not change significantly after PRL
treatment on the protein level (Fig S6A–D), Nor did PRL
treatment significantly decrease PRLR expression at the gene or
protein level in organ-cultured skin (Fig S6E-I). By ELISA, there
was no evidence of PRL secretion into the media in either skin
organ or HF culture (Fig S6J).
Discussion
This study demonstrates that contrary to a previous report
[9], human non-scalp skin not only expresses PRLR on the gene
and protein levels, but also PRL mRNA and protein. That PRL
expression increased during human truncal skin organ culture
shows that intracutaneous PRL expression occurs even in the
absence of vascular, neural, and hypothalamic stimuli. We also
demonstrate that PRL and PRLR expression is time-dependent, at
least in vitro, using a well established immunohistomorphological
method for quantifying protein expression, measuring the intensity
of protein IR in situ [20,21,33,36,43,58,59,60]. These data from
serum-free organ culture demonstrate that human skin can
produce PRL, and reconcile apparently conflicting data fom the
literature. Fully consistent with Slominski et al [9] we were unable
to identify PRL gene expression in 2/3 subjects at day 0. However,
PRL became detectable during serum free organ culture. It will be
intriguing to study whether this temporally regulated PRL gene
expression is significant in vivo, for example in response to skin
trauma or psychological stress.
While we found no evidence that PRL is actively secreted by the
skin and/or HFs, PRL secretion into the culture medium cannot
be excluded, since it could well have been below the detection limit
of the employed ELISA, and may have been detectable with the
more sensitive Nb2 cell proliferation bioassay [37].
Importantly, the study identifies the key stress mediator and
neurogenic inflammation-associated neuropeptide, substance P,
and the pro-inflammatory cytokines, IFNc and TNFa as
regulators of PRL protein expression in situ in human truncal skin
and HFs. In contrast, dopamine, the classical negative regulator of
pituitary PRL secretion, did not exert a significant regulatory effect
on PRL expression in human HFs. We deliberately used
dopamine itself rather than specific dopamine receptor agonists,
for example cabergoline or bromocriptine, as there is no evidence
at present that human HFs, or even skin, express the dopamine
receptor 2 to which these agents bind. To data, only dopamine
receptor 1 transcripts have been demonstrated in human skin and
HFs [61]. Unlike the compartment-specific differences that TRH
exerts on cutaneous pigmentation [62], there was no evidence that
there are skin compartment-specific differences in the regulation of
PRLR by its own ligand.
Figure 7. STAT5 phosphorylation is increased by PRL treatment in serum-free skin organ culture. Treatment with PRL (400 ng/ml) in
serum-free organ culture increased epidermal STAT5 phosphorylation in all 3 of the individuals investigated. 3 females aged 42–63 years as in Fig 1(J)
and 2(I). Arrows show phosphorylated STAT5 as detected by monoclonal rabbit antibody recognising STAT5a and b phosphorylated at Tyr 694.
doi:10.1371/journal.pone.0060819.g007
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Our group has consistently identified PRL and PRLR
expression in female corporal skin from several locations, in a
distribution pattern strikingly similar to that seen in scalp skin [20].
However, a recent study has called attention to the substantial
variability in the sensitivity and specificity of commercially
available PRLR antibodies [63]. Nevertheless, the PRLR staining
we report here is consistent with that reported in the literature,
which had been using a different PRLR antibody [1]. Due to our
existing ethics approval (anonymized samples, with only gender,
age, and skin location provided) we are unable to gain information
regarding donors’ menopausal status. Given that post-menopausal
PRL levels tend to be lower than those in pre-menopausal females
[64], possibly as a result of decreased circulating estrogen levels, it
is conceivable that the regulation of extra-pituitary PRL expres-
sion may also be influenced by menopausal status. However, in
other extra-pituitary tissues, for example, glandular breast
explants, estradiol did not regulate PRL release [65]. Moreover,
the local tissue inflammatory milieu may also influence PRL
expression, particularly in the context of psoriasis [28]. Follow-up
studies would profit from taking these potential modulators of
extrapituitary PRL/PRLR expression into account.
Given that the expression of the pituitary hormone pro-
opiomelanocortin (POMC) in murine skin is reportedly up to
10,000 times lower than that in the pituitary [66] highly sensitive
methods are required to investigate PRLR expression. Further-
more, another issue to be considered in expression mapping is the
generation of isoforms from alternative splicing. This process may
prevent detection of some transcripts; well illustrated in the case of
CRH receptor type 1[67]. We specifically used qRT-PCR to
provide quantitative data on the levels of PRL/PRLR transcript in
the organ cultured skin/HFs so as to complement the quantitative
protein expression in situ data. However, in follow-up studies, in-
situ hybridization data are desirable to confirm the location of
PRL/PRLR transcript expression in human skin and HFs, as are
Western Blots and fully quantitative ELISA analyses performed on
protein extracts, provided the much larger quantities of human
tissue that are needed for the latter analyses are available.
To confirm the activity of PRLR-mediated signaling, STAT5
phosphorylation was also investigated at the protein level. In all
three subjects tested, PRL treatment increased STAT5 phosphor-
ylation at day 7. This provides preliminary evidence that
cutaneous PRLR-mediated signaling can be transduced via the
canonical Jak2/STAT5 pathway. However, the extent to which
other recognised signaling pathways/proteins may be involved, for
example the Ras/Raf/MAPK, and Src kinases or PI3K/Akt
pathways, needs to be clarified in future studies. The data also
provides indirect evidence that the long form of the PRLR is
expressed in the skin as short PRLR isoforms are unable to
activate Jak/STAT pathway.
The observed effect of IFNc on PRL expression did not seem to
be related to changes in PRLR expression, since the latter was
unchanged. PRL is an important immunomodulator, possibly with
overall pro-inflammatory effects in response to the immunosup-
pressive effects of stress [68]; consistent with the finding that IFNc
increases PRL expression in the HF. In terms of HF pathophys-
iology, lesional alopecia areata skin has been shown to have
increased levels of IFNc mRNA [69] and IFNc has potent catagen
(HF regression) promoting effects [39]. Intriguingly, PRL can exert
the same effects [1], raising the possibility that IFNc may partially
exert its effects via alterations in intrafollicular PRL expression.
Future studies utilizing pure PRLR antagonists could address this
question [21]. Moreover, PRL also modulate expression of the
interferon regulatory factor-1 gene [11], which underscores the
potential importance of the ‘‘PRL-IFNc link’’ in human skin
biology and pathology.
In addition to stimulators of PRL and/or PRLR expression we
have also identified inhibitors. Substance P decreased PRL IR in
the epidermis, whilst TNFa decreased PRL and PRLR IR in the
HF. Given that substance P is a key mediator of neurogenic skin
inflammation [70], and may partially explain the effects of
psychological stress on hair growth in alopecia areata and telogen
effluvium [33], it is interesting to note that substance P decreased
PRL IR. This is well in line with similar substance P effects
reported on pituitary PRL production in rodents [71].
TNFa treatment actually increased PRLR transcription in
cultured ORS keratinocytes, in contrast to its effect on PRLR
protein expression in the ORS of the intact HF. This raises the
question of whether the regulation of PRLR expression in human
HF epithelium in situ depends on the presence of as yet
unidentified HF mesenchyme-derived factors. The down-regula-
tion of follicular PRLR expression by TNFa is also intriguing in
view of the importance of TNFa in both inflammatory dermatoses
such as psoriasis [51] and hair growth [38]. In follow-up studies,
the epidermal regulation of PRL and/or PRLR protein expression
by TNF deserves to be characterized, since increased TNFa and
PRL levels in psoriasis [28] may both result in a decrease in PRLR
expression. The current serum-free human skin organ culture
model permits one to investigate whether the regulation of PRL
and/or PRLR is altered in inflammatory skin disorders, for
example in psoriasis. Also, novel PRLR antagonists [18] can be
utilized to determine whether they effectively counteract any
cutaneous effects of PRL, for example on keratinocyte prolifera-
tion [72] and angiogenesis [73].Moreover, laser-capture micro-
dissection may allow the identification of compartment specific
PRL gene expression in the skin, although given that the skin and
HF contain immune cells, it may be difficult to determine the
contribution they play to intracutaneous PRL production.
It is now appreciated that PRL is an important regulator of
human hair growth [1,6,21,74,75] and may be implicated in the
pathobiology of common, chronic skin diseases [6,27] including
psoriasis [3,4,5,28,52,76,77] and lupus erythematosus [7,78,79].
Therefore, targeting cutaneous PRL production and PRLR
expression via these and other recently identified regulators of
intracutaneous PRL and PRLR expression in human skin and its
appendages [20] may represent a novel dermatotherapeutic
strategy.
Supporting Information
Figure S1 CRH does not alter PRL protein expression in
human skin. PRL IR in the control skin (A) was not significantly
different to that in (B) CRH treated skin. Positive and negative
controls are shown in (C) and (D). Negative control was via
omission of the primary antibody and the outer root sheath of the
hair follicle and sebaceous gland served as internal positive
controls. Quantitative IR measurement, the epidermis, is shown in
(A) and evaluation in (E). Results were pooled from 3 R subjects,
aged 45–57 years.
(TIF)
Figure S2 Thyroid hormones have no significant effect
on PRL and PRLR expression in human skin. (A) PRL IR
in the epidermis of control skin was not significantly different to
that in skin treated with (B) triiodothyronine (T3) or (C) thyroxine
(T4) for 24 hours as demonstrated by quantitative measurement of
PRL IR (D). Results pooled from 5R subjects aged 45–71 years.
Similarly, PRLR IR in the epidermis of control skin (E) was not
significantly different in (F) T3 or (G) T4 treated skin as quantified
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in (H). Results pooled from 3R subjects aged 56–71 years. Indeed,
neither 24 hours of treatment with T3 (I) or T4 (J) significantly
affected PRLR gene expression. Results pooled from 2R subjects
aged 46 and 60 years.
(TIF)
Figure S3 Dopamine does not alter PRL protein expres-
sion in human hair follicles. PRL IR in control hair follicles
(A) was not significantly different to that in Dopamine (1000 nM)
treated hair follicles (B). Negative control (C). Quantitative IR
measurement revealed no significant differences across the range
of Dopamine concentrations tested (D) 1000 nM (pooled results
from 3R subjects, aged 47–68 years, 21–22 HFs per group in total)
and (E) 10–100 nM in 2R subjects aged 47–64, 15–21 HFs per
group in total). Areas measured by image J are shown in (A).
(TIF)
Figure S4 Dopamine does not regulate PRLR expres-
sion at the gene or protein level in human hair follicles.
PRL IR in the control hair follicles (A) was unchanged compared
with that after Dopamine (B) 10 nM, (C) 100 nM or (D) 1000 nM
treatment. (E) Negative control. Quantitative IR measurement
revealed no significant differences across the range of Dopmaine
concentrations tested (F) 1000 nM (pooled results from 3R
subjects, aged 47–68 years, 20–24 HFs per group in total) and
(G) 10–100 nM in 2R subjects aged 47–64, 14–18 HFs per group
in total). (H) Dopamine 1000 nM exerted no significant effect on
steady PRLR gene expression after 48 hours (56 R subject).
(TIF)
Figure S5 IFNc has no effect on PRLR immunoreactivity
in human hair follicles at the gene or protein level. (A)
PRLR IR in the outer root sheath of control hair follicles (black
arrows) was unchanged by treatment with (B) IFNc 75 IU/ml. (C)
Negative control. (D) Quantitative analysis showed no significant
difference in PRLR. Results were pooled from 3R subjects, aged
44–68 years, 13–16 HFs in total from three patients. **Arbitrary
units could not be normalised due to low number of anagen hair
follicles. Results were pooled from the same subjects as in Fig 4. (E)
There was no evidence that IFNc influenced PRLR gene
expression. Results were pooled from 2R aged 53–66 years.
(TIF)
Figure S6 No evidence of compartment specific regula-
tion of PRLR expression in human skin. PRLR IR is not
significantly reduced by PRL 400 ng on the protein level in the
outer root sheath of HFs after serum-free organ culture (A–D).
Results pooled from 4 R subjects (aged 49–68 years). 23 HFs per
group in total. Moreover, epidermal PRLR IR was also
unchanged after organ-culture (E–H). Results pooled from 3 R
subjects described in Fig 2. This correlated with no significant
difference at the gene transcription level after 7 days in pooled
results from three subjects (I) as described in Fig 1. Scale bars
represent 50 mm. PRL was not detectable in the conditioned
media in either skin or HF organ culture. Level of detectability
shown with solid black line (J).
(TIF)
Table S1 The differential regulation of pituitary and
extrapituitary PRL synthesis and release. There is, at
times, a bewildering array of seemingly contradictory regulatory
effects on PRL and PRLR expression between depending on the
site of PRL production. Some of these are due to methodological
factors. Abbreviations: T3:triiodothyronine, T4:thyroxine.
(DOC)
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